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The pregnancy specific #1-glycoprotein (SP1) is
synthesized by the human placenta and secreted
into the maternal circulation. However, SP1 does
not seem to be specific to pregnancy since it has
been detected by radioimmunoassay in sera from 3
to 54% of healthy persons (Searle et al., 1978;
Wurz, 1979; Tatarinov, 1980) and in sera from
patients with a variety of malignant diseases, for
instance 8-55% of breast cancer patients (Searle et
al., 1978; Wiirz, 1979; Tatarinov, 1980), depending
on the detection limit of the assay. By means of a
histological immunoperoxidase technique SP1 has
been demonstrated in 37-76% of malignant
tumours of the breast (Horne et al., 1976; Inaba et
al., 1980; Walker, 1981). Furthermore, the survival
time was significantly longer for women with SP1
negative tumours than those with SP1 positive
tumours (Horne et al., 1976).
A prospective study (3 years) was undertaken to
clarify the value of determining SP1 in serum taken
preoperatively and/or detecting SP1 in tumour
tissue as a prognostic indicator in the selection of
patients with malignant breast tumours for chemo-
therapy.
The study comprised 113 women selected at
random from patients admitted to the Department
of Surgery during the course of about 6 months for
investigation of and treatment for a suspected
breast tumour. The histological classification was
done as recommended by the WHO (Azzopardi et
al., 1982). Benign breast disease was found in 79
patients. The histological diagnoses were mammary
dysplasia/fibrocystic disease (66 patients), fibro-
adenoma (5 patients), intraductal papilloma (5
patients), lipoma (2 patients), and phyllodes tumour
(1 patient). Malignancy was histologically
confirmed in 34 women, 7 of whom had previously
had a contralateral malignant breast tumour,
whereas breast cancer had previously not occurred
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in the remaining. Twenty four of the latter were
given a total mastectomy with partial axillary
dissection and, depending on the histological
findings, were treated postoperatively with radio-
therapy and systemic adjuvant treatment (Andersen
et al., 1981). The other 3 patients had only the
tumour removed because of age or a histological
diagnosis of non-invasive ductal carcinoma. The
seven patients with previous contralateral breast
tumours weie given individual treatment. The
patients with cancer were followed up for at least 3
years after operation.
The determination of SP1 in serum was
performed with a highly sensitive radioimmuno-
assay described elsewhere (Sorensen and
Trentemqller, 1983). The assay consisted of
standards, controls, unknown samples and controls
for non-specific binding (NSB) of 1251-SP1 in
standards and in all samples. As NSB of 1251-SPI
for standards and samples was different (usually 7-
8% and 5-6%, respectively) the percentage of
binding for standards and samples was calculated
by subtracting the corresponding NSB from anti-
body bound radioactivity and the total amount of
radioactivity added, respectively. A spline function
programme (Reinsch, 1967) was used to calculate
the SP1 concentration in the samples.
Serial dilution of 4 serum samples with a concen-
tration of SP1>2.0igl- were parallel with the
standard curve (Figure 1 (a-d)). Furthermore, if
various amounts of SP1, 25-40 pg, (pregnancy
serLm) were added to a non-pregnancy serum pool
(from patients) a constant difference was found,
corresponding to an SP1 concentration of 1.4gI-1.
However, the dose-response for samples with low
SP1 values was less steep than the standard curve
(Figure 1 (e, f)).
Interassay variation was estimated by repeated
analysis of a normal serum pool and a pregnancy
serum pool diluted 1:50 and 1:25 with assay buffer.
The mean values were 1.3, 2.3 and 4.5 pg1-'
and the coefficient of variation was 11.8-13.2%
(n= 10-14).
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Figure 1 Parallelism of standard curve (X) and serial
dilutions of serum samples (0) from patients with
high (a-d) and low (e-f) concentrations of SP1.
The detection limit of the assay was 0.5pg 1,
the smallest concentration of SP1 which could be
distinguished from a standard without SP1 (the zero
standard). A 95% confidence interval for the
estimate of zero standard (n=15) differed from a
95% confidence interval for the estimate of
0.5MgI-
I standard (n = 15).
The pathological material consisted of con-
ventional formalin-fixed, wax-embedded histological
sections of tumour tissue from the patients. By
means of indirect immunoperoxidase technique
(Heyderman, 1979), the breast tumours were
investigated for the presence of SP1 with rabbit
anti-human SP1 (Lot No. 018 C, Dakopatt,
Denmark) at a dilution of 1:30. The degree of
staining was assessed in the epithelium of ducts,
within the lumen, in myoepithelial cells, in stroma
and if present, in the cells of the tumour. If no
reaction or a doubtful weak reaction developed
the staining was regarded as negative. When
staining was positive the most positive staining was
registered as weak or strong.
Sections from SP1 positive breast carcinomas to
confirm antibody specificity were incubated with
antiserum, which had been absorbed with purified
SP1 (S0rensen & Trentem0ller, 1983). The staining
completely disappeared. In addition no colour
reaction was apparent in the sections when buffer
replaced anti-SP1 antiserum.
The tumours were classified by H & E stained
sections.
Almost all the values of SP1 in the sera of
women with benign breast tumours were from <0.5
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Figure 2 SP1 level in sera and degree of staining for
SP1 in tumour tissue from patients with benign or
malignant breast tumours. Tumour cells negative or
uncertain weak reaction (*), tumour cells weak SP1
positive (0), tumour cells strong SP1 positive (U).
to 1.6 ugl-1 (Figure 2). One woman had a slightly
increased concentration of 2.5 gl- 1 and another on
hormonal substitution therapy with oestradiol and
norgestrel had an inexplicable high value of
24,Mgl-'. In 10 patients with benign tumours and
previous contralateral breast cancer the range was
similar to that of women with malignant breast
disorders except for one patient, who had an
increased concentration of 9.7Mg1 1. She died
during the follow-up period from a recurrence of
her breast cancer. In 34 patients with breast cancer
only 3 patients had a slightly increased concen-
tration of SP1 (1.8-2.1 Mgl-1), whereas 31 patients
had an SP1 concentration ranging from <0.5pgl-1
to 1.5Mg1-1, corresponding to the level in patients
with benign breast diseases.
Immunohistochemical investigation with indirect
immunoperoxidase technique for SP1 in various
benign breast diseases was negative except in 2
patients with intraductal papilloma where a few
tumour cells showed weak SP1 activity and in 2
patients with a simultaneous relapse of their first
breast cancer where normal duct epithelium showed
slight activity. SP1 could be demonstrated in
tumour cells in 6/34 (18%) malignant breast
tumours. In all tumours the SP1 reactivity was
heterogeneous varying from negative to different
degrees of positive staining. The SP1 reactivity was
in all tumours localized in the cytoplasm of the
tumour cells (Figure 3). Only one of 6 patients with
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Figure 3 Mammary carcinoma incubated with anti-SP1. A: tumour cells without SP, reaction. B: tumour
cells with SP1 localized in the cytoplasm ofcells (arrows). Immunohistochemical staining x 590 n: nucleus.
positive SP1 staining in the tumour died from the
breast cancer during the observation period of 3.
years (Table I).
The detection limit chosen does not include non-
specific interference (noise) (Hunter & Bennie,
1979). When sera from subjects who might be
expected to have little or no SP1 in the circulation
were assayed, responses were close to the detection
limit, but significant. Determinations of these
samples in two dilutions seemed to display
responses which were less steep than the
corresponding part of the standard curve, Figure 1
(e, f). This might indicate non-specificity - although
the values were derived from the upper more
imprecise part of the curve - or presence of a minor
SP1 component, SP1(y), (Sorensen & Trentemqller,
1983). The non-specific reactivity may be large
enough to obscure specific determinations,
particularly at low levels (Hunter & Bennie, 1979).
However, a parallelism was found betweenr the
standard curve and dilutions of serum samples with
an SP1 concentration >2pg 1- (Figure 1).
A range for serum SP1 in women with benign
breast tumour was obtained which agreed with that
in healthy subjects (Kaminska et al., 1979; Wiirz,
1979; Rosen et al., 1982). For patients with breast
cancer the SP1 concentration was of the same level
as that in women with benign tumours. No values
above 3pgl-1 were found which agreed with other
studies (Bremmer et al., 1981; Rosen et al., 1982),
but conflicted with studies previously reported to
have from 22% to 29% of SP1 determinations
>>3ygl-' (Searle et al., 1978; Wurz, 1979) and 8%
to 11% >l0pgI-' (Wiirz, 1979; Tatarinov, 1980).
In a less sensitive assay with a detection limit of
lOpgl-1, SP1 was observed in only one of 42
patients with malignant breast disorders
(Grudzinskas et al., 1980). However, SP1 has been
measured in the majority of homogenates of breast
tumour tissue, both malignant and benign
(Bremmer et al., 1981) although the concentrations
measured were close to the detection limit.
By means of an indirect immunoperoxidase
technique, SP1 was absent in all benign tumours
except 4. Two of these had intraductal papillo-
matosis. In another study no benign tumours out of
12 were found to be SP1 positive (Home et al.,
1976). In malignant breast tumours SP1 was present
in only 17% of the patients compared with 76, 53
and 37% in other studies (Horne et al., 1976; Inaba
et al., 1980; Walker, 1981). The explanation may be
differences in the methods, the antisera, or the
representativeness of the histological sections since
SP1 positive cells are irregularly distributed in the
tumour, or in the composition of the tumours. No
correlation seems to exist between the intensity of
SP1 staining in the tumour and the serum SP1 level.
Strong SP1 positive tumours had normal serum SP1
concentration and vice versa. The significance of the
degree of differentiation for the presence of SP1 is666 S. SQRENSEN et al.
Table I Clinical and histological findings in breast cancer patients with serum SPI> 1.6pg 1 or positive SP1 staining of
the tumour
Histological Histologically involved Preoperative S-SPF
diagnosis (WHO) ratio oflymph nodes tumour size (cm) Relapse ugl-l
S-SP1> 1.6MgI-' Invasive ductal carcinoma / 2 No 1.8
Invasive ductal carcinoma 11/16 No 1.9
Mucinous carcinoma 0/7 2 No 2.1
Positive SP1 Invasive ductal carcinoma 4/18 11 No <0.5
staining Intraductal carcinoma - 2 Yes,died 0.6
Papillary carcinoma 0/5 2l No,died 0.8
Invasive ductal carcinoma Yes 0.9
Invasive ductal carcinoma 0/7 2- No 1.2
Invasive ductal carcinoma / 2 No 1.8
uncertain. A low occurrence of SP1 was found
histochemically in poorly differentiated carcinomas
(Walker, 1981), whereas homogenates of poorly
differentiated carcinomas had a higher concen-
tration of SP1 than those of well differentiated
tumours (Bremmer et al., 1981).
The presence of SP1 in malignant tumours might
indicate a shorter survival (Home et al., 1976), but
the low incidence of SP1 positive tumours and a
follow-up period of only 3 years in this study
meant that the number of patients was too small to
permit satisfactory statistical analysis. Furthermore,
various postoperative chemotherapeutic regimes
may influence the survival.
In conclusion, quantification of SP1 in sera or an
investigation for the presence of SP1 in tumour
tissue seem to be of little clinical value in the
management of patients with breast cancer. On the
other hand, SP1 has been demonstrated in some
breast cancers and it remains to be elucidated
whether this detection indicates local production or
an uptake of SP1 from the circulation. Finally, a
study is required to determine whether the serum
SP1 levels obtained are truly being assayed or arise
from a matrix effect in the radioimmunoassay.
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